



# ASX Announcement

**For immediate release**

23 October 2012

## **CSL Historical Financial Performance in US Dollars**

In February 2012, the company announced its decision to move to US dollar reporting commencing with the 2012/13 financial year. US dollars are the pharmaceutical industry standard currency for reporting purposes. The move also reflects the increasing predominance of the Company's worldwide sales and operations in US dollars.

To assist investors during the transition the Company is today lodging with the Australian Securities Exchange sets of financial statements for the first half and full year financial 2012, restated in US dollars. A 5 year financial summary in US dollars is also provided.

The financial statements have been prepared using Accounting Policies consistent with those applied in the preparation of CSL Limited's audited consolidated financial statements for these periods. These accounting policies can be found in Note 1 of the CSL Limited Financial Report contained in the CSL Annual Report for the relevant period and available from the company's website [www.csl.com.au](http://www.csl.com.au). The attached financial statements are unaudited but have been subject to Agreed Upon Procedures carried out by Ernst & Young. We expect these to form the prior comparable period disclosures in the CSL Group Financial Statements for the half year ended 31 December 2012 (to be reviewed by Ernst & Young) and full year ended 30 June 2013 (to be audited by Ernst & Young).

The five year financial summary has been prepared by translating the Group's financial statements using exchange rates and accounting policies applicable to the relevant period.

For further information, please contact:

Mark Dehring  
Head of Investor Relations  
CSL Limited  
Telephone: +613 9389 2818  
Email: [mark.dehring@csl.com.au](mailto:mark.dehring@csl.com.au)

**CSL Group**  
**Five year summary presented in US Dollars**

**Consolidated Income Statement**

For the year ended 30 June

US\$ Millions

	Jun 2008	Jun 2009	Jun 2010	Jun 2011	Jun 2012	Dec 2011
	12 Months	12 Months	12 Months	12 Months	12 Months	6 Months
<b>Continuing operations</b>						
Sales revenue	3,179	3,412	3,909	4,097	4,616	2,324
Cost of sales	(1,724)	(1,784)	(1,918)	(2,083)	(2,390)	(1,253)
<b>Gross Profit</b>	<b>1,455</b>	<b>1,628</b>	<b>1,991</b>	<b>2,014</b>	<b>2,227</b>	<b>1,071</b>
Other revenues	220	319	149	131	197	105
Research and development expenses	(203)	(226)	(278)	(323)	(370)	(168)
Selling and marketing expenses	(355)	(359)	(429)	(434)	(506)	(232)
General and administration expenses	(225)	(306)	(209)	(207)	(238)	(129)
Finance costs	(45)	(46)	(16)	(14)	(41)	(15)
<b>Profit before income tax expense</b>	<b>848</b>	<b>1,010</b>	<b>1,207</b>	<b>1,167</b>	<b>1,270</b>	<b>634</b>
Income tax expense	(221)	(164)	(286)	(249)	(246)	(130)
<b>Profit attributable to members of the parent company</b>	<b>627</b>	<b>845</b>	<b>921</b>	<b>918</b>	<b>1,024</b>	<b>504</b>

**Segment information**

For the year ended 30 June

US\$ Millions

	Jun 2008	Jun 2009	Jun 2010	Jun 2011	Jun 2012	Dec 2011
	12 Months	12 Months	12 Months	12 Months	12 Months	6 Months
<b>Sales</b>						
- CSL Behring	2,578	2,862	3,181	3,494	3,909	1,950
- Other Human Health	656	636	840	721	853	441
- IP Licensing						
- Intersegment Elimination	(54)	(86)	(112)	(117)	(145)	(67)
Total sales	3,179	3,412	3,909	4,097	4,616	2,324
<b>Total Segment Revenue</b>						
- CSL Behring	2,590	2,876	3,188	3,499	3,913	1,953
- Other Human Health	670	643	857	726	862	446
- IP Licensing	170	142	92	93	142	82
- Unallocated / Intersegment Elimination	(32)	71	(80)	(90)	(104)	(51)
Total Consolidated Revenue	3,399	3,732	4,057	4,228	4,814	2,429
<b>EBIT</b>						
- CSL Behring	715	887	990	1,136	1,231	583
- Other Human Health	174	9	141	(23)	(38)	(5)
- IP Licensing	-	104	84	80	126	73
- Unallocated	(28)	9	(26)	(39)	(51)	(17)
Total Consolidated EBIT	861	1,008	1,188	1,154	1,268	634
<b>EBITDA</b>						
- CSL Behring	-	978	1,089	1,253	1,359	647
- Other Human Health	-	51	177	25	7	15
- IP Licensing	-	104	84	80	126	73
- Unallocated	-	10	(24)	(34)	(45)	(15)
Total Consolidated EBITDA	987	1,143	1,326	1,324	1,446	720

**CSL Group**  
**Five year summary presented in US Dollars**

**Consolidated Balance Sheet**

As at 30 June	Jun	Jun	Jun	Jun	Jun
Selected items US\$ Millions	2008	2009	2010	2011	2012
Cash & cash equivalents	675	2,051	853	515	1,171
Trade and other receivables	682	719	752	869	784
Inventories	1,153	1,235	1,239	1,565	1,483
Other Current Assets	1	11	0	19	7
<b>Total Current Assets</b>	<b>2,511</b>	<b>4,015</b>	<b>2,845</b>	<b>2,968</b>	<b>3,445</b>
Trade and other receivables	8	8	6	5	10
Property Plant & Equipment	939	972	1,029	1,297	1,381
Intangible assets	876	791	814	983	865
Other Non-Current Assets	183	191	171	192	200
<b>Total Non-Current Assets</b>	<b>2,005</b>	<b>1,962</b>	<b>2,021</b>	<b>2,478</b>	<b>2,456</b>
<b>Total Assets</b>	<b>4,517</b>	<b>5,977</b>	<b>4,865</b>	<b>5,447</b>	<b>5,901</b>
Trade and other payables	423	539	413	530	536
Interest-bearing liabilities and borrowings	123	270	22	243	170
Other Current Liabilities	258	186	235	243	245
<b>Total Current Liabilities</b>	<b>804</b>	<b>994</b>	<b>670</b>	<b>1,017</b>	<b>950</b>
Trade and other payables	-	-	-	4	15
Interest-bearing liabilities and borrowings	794	313	372	204	1,120
Other Non-Current Liabilities	219	238	232	305	339
<b>Total Non-Current Liabilities</b>	<b>1,013</b>	<b>550</b>	<b>604</b>	<b>513</b>	<b>1,474</b>
<b>Total Liabilities</b>	<b>1,817</b>	<b>1,545</b>	<b>1,274</b>	<b>1,530</b>	<b>2,425</b>
Retained Earnings	1,548	2,145	2,688	3,162	3,713
<b>Total Equity</b>	<b>2,699</b>	<b>4,432</b>	<b>3,591</b>	<b>3,917</b>	<b>3,477</b>

**Miscellaneous Metrics**

For the year ended 30 June	Jun	Jun	Jun	Jun	Jun	Dec
US\$ Millions	2008	2009	2010	2011	2012	2011
	12 Months	12 Months	12 Months	12 Months	12 Months	6 Months
Basic EPS (cents)	113.90	142.02	162.55	169.81	197.20	95.30
Cash Flow from Operations	620	759	1,029	1,005	1,206	539
Dividends (US cents per share)	41.07	51.64	70.00	78.07	86.49	37.57
Payments for Property Plant & Equipment	197	195	215	197	309	148
Payments for Intangible Assets	0	0	0	14	14	5
Net Interest Expense / (Income)	13	(1)	(19)	(13)	(2)	(0)
Depreciation/Amortisation	127	135	137	170	178	86
<b>Behring Product Sales</b>						
Immunoglobulins	871	1,063	1,197	1,494	1,722	
Specialty Products	354	414	475	520	618	
Albumin	229	267	279	286	314	
pdCoag	525	517	544	527	557	
Helixate®	407	434	489	486	502	
<b>Total Product Sales</b>	<b>2,386</b>	<b>2,695</b>	<b>2,984</b>	<b>3,313</b>	<b>3,713</b>	

# **CSL Limited**

ABN: 99 051 588 348

## **Abbreviated Interim Financial Statements presented in USD for the information of shareholders**

**for the half year ended 31 December 2011**

These financial statements have been prepared using the same accounting policies as applied to the CSL Limited half year financial statements for the period ended 31 December 2011 issued on 22 February 2012 and available on the Company's website [www.csl.com.au](http://www.csl.com.au),

with the exception of the following:

The half year financial statements were presented in A\$000 while this report adopts a Presentation Currency of US Dollars and is presented in US\$m.

**CSL Limited**  
**Consolidated Statement of Comprehensive Income in USD**  
**For the half-year ended 31 December 2011**

		<b>Consolidated Entity</b>
		<b>December</b>
		<b>2011</b>
	<b>Notes</b>	<b>US\$m</b>
Sales revenue		2,324.0
Cost of sales		(1,252.9)
Gross profit		1,071.1
Other revenue	2(a)	105.4
Research and development expenses		(167.4)
Selling and marketing expenses		(231.5)
General and administration expenses	2(c)	(128.8)
Finance costs	2(b)	(14.9)
Profit before income tax expense		633.9
Income tax expense	3	(129.6)
<b>Net profit for the period</b>		<b>504.3</b>
Other comprehensive income		
Exchange differences on translation of foreign operations, net of hedges on net foreign investments	9	(319.0)
Actuarial gains/(losses) on defined benefit plans, net of tax		(33.7)
Mark to market adjustment on available-for-sale financial assets		(1.0)
Total of other comprehensive income/(expense)		(353.7)
Total comprehensive income for the period		150.6
<b>Earnings per share (based on net profit for the period)</b>		<b>Cents</b>
Basic earnings per share	4	96.25
Diluted earnings per share	4	96.07

**CSL Limited**  
**Consolidated Balance Sheet in USD**  
**As at 31 December 2011**

		Consolidated Entity	
		December 2011	June 2011
	Notes	US\$m	US\$m
<b>CURRENT ASSETS</b>			
Cash and cash equivalents	5	1,317.2	515.2
Trade and other receivables		842.4	869.0
Inventories		1,414.0	1,564.8
Other financial assets		4.3	19.3
<b>Total Current Assets</b>		<b>3,577.9</b>	<b>2,968.3</b>
<b>NON-CURRENT ASSETS</b>			
Trade and other receivables		4.5	4.9
Other financial assets		-	2.4
Property, plant and equipment	6	1,279.5	1,297.5
Deferred tax assets		179.9	187.2
Intangible assets		882.0	983.4
Retirement benefit assets		-	2.8
<b>Total Non-Current Assets</b>		<b>2,345.9</b>	<b>2,478.2</b>
<b>TOTAL ASSETS</b>		<b>5,923.8</b>	<b>5,446.5</b>
<b>CURRENT LIABILITIES</b>			
Trade and other payables		429.7	530.4
Interest-bearing liabilities		168.5	243.1
Current tax liabilities		121.6	141.5
Provisions		89.8	95.2
Deferred government grants		1.0	1.1
Derivative financial instruments		3.6	5.4
<b>Total Current Liabilities</b>		<b>814.2</b>	<b>1,016.7</b>
<b>NON-CURRENT LIABILITIES</b>			
Trade and other payables		8.8	4.3
Interest bearing liabilities	7	1,127.3	204.3
Deferred tax liabilities		113.7	131.3
Provisions		27.5	30.6
Deferred government grants		19.9	20.3
Retirement benefit liabilities		147.8	122.4
<b>Total Non-Current Liabilities</b>		<b>1,445.0</b>	<b>513.2</b>
<b>TOTAL LIABILITIES</b>		<b>2,259.2</b>	<b>1,529.9</b>
<b>NET ASSETS</b>		<b>3,664.6</b>	<b>3,916.6</b>
<b>EQUITY</b>			
Contributed equity	8	(406.0)	(228.0)
Reserves	9	668.5	982.1
Retained earnings		3,402.1	3,162.5
<b>TOTAL EQUITY</b>		<b>3,664.6</b>	<b>3,916.6</b>

**CSL Limited**  
**Consolidated Statement of Changes in Equity in USD**  
**For the half year ended 31 December 2011**

	Ordinary shares	Foreign currency translation reserve	Share based payment reserve	Available- for-sale investment reserve	Retained earnings	Total
	US\$m	US\$m	US\$m	US\$m	US\$m	US\$m
<b>At 1 July 2011</b>	(228.0)	901.1	82.2	(1.2)	3,162.5	3,916.6
Profit for the period	-	-	-	-	504.3	504.3
Other comprehensive income	-	(319.0)	-	(1.0)	(33.7)	(353.7)
<b>Total comprehensive income for the half year</b>	-	(319.0)	-	(1.0)	470.6	150.6
<b>Transactions with owners in their capacity as owners</b>						
Share based payments	9	-	6.4	-	-	6.4
Dividends	-	-	-	-	(231.0)	(231.0)
Share buy back	8	(181.8)	-	-	-	(181.8)
Share issues	-	-	-	-	-	-
- Employee share scheme	8	3.8	-	-	-	3.8
<b>Balance as at 31 December 2011</b>	<b>(406.0)</b>	<b>582.1</b>	<b>88.6</b>	<b>(2.2)</b>	<b>3,402.1</b>	<b>3,664.6</b>

**CSL Limited**  
**Consolidated Statement of Cash Flows in USD**  
**For the half-year ended 31 December 2011**

		<b>Consolidated Entity</b>
		<b>December</b>
		<b>2011</b>
		<b>US\$m</b>
	<b>Notes</b>	
<b>Cash flows from Operating Activities</b>		
Receipts from customers (inclusive of goods and services tax)		2,430.7
Payments to suppliers and employees (inclusive of goods and services tax)		(1,747.8)
		<b>682.9</b>
Interest received		9.2
Income taxes paid		(140.9)
Borrowing costs		(12.4)
<b>Net cash inflow / (outflow) from operating activities</b>		<b>538.8</b>
<b>Cash flows from Investing Activities</b>		
Proceeds from sale of property, plant and equipment		0.4
Payments for property, plant and equipment		(147.6)
Payments for intangible assets		(5.4)
Receipts from other financial assets		0.8
<b>Net cash inflow / (outflow) from investing activities</b>		<b>(151.8)</b>
<b>Cash flows from Financing Activities</b>		
Proceeds from issue of shares		4.0
Payment for shares bought back		(181.8)
Dividends paid		(231.0)
Receipts (payments) on closure of foreign exchange hedges		0.6
Proceeds from borrowings	7	1,112.4
Repayment of borrowings	7	(242.2)
<b>Net cash inflow / (outflow) from financing activities</b>		<b>462.0</b>
Net increase (decrease) in cash and cash equivalents		849.0
Cash and cash equivalents at the beginning of the period		514.6
Exchange rate variations on foreign cash and cash equivalent balances		(46.4)
<b>Cash and cash equivalents at the end of the period</b>		<b>1,317.2</b>
<b>Reconciliation of cash and cash equivalents</b>		
Cash and cash equivalents at the end of the period as shown in the statement of cash flows is reconciled as follows:		
Cash and cash equivalents	5	1,317.2
Bank overdrafts		-
		<b>1,317.2</b>



# CSL Limited

## Notes to the Financial Statements in USD

### For the half-year ended 31 December 2011

#### 1 Segment Information

Reportable segments are:

- (a) CSL Behring – manufactures, markets and develops plasma products
- (b) Intellectual Property Licensing – revenue and associated expenses from the licensing of Intellectual Property generated by the Group to unrelated third parties
- (c) Other Human Health – comprises CSL Biotherapies, which manufactures and distributes biotherapeutic products, and Research & Development.

Research & Development expense is allocated in accordance with management's expectation as to where a project's value will be realised. Where this is uncertain the expense is allocated to Other Human Health.

	CSL Behring December 2011 US\$m	Intellectual Property Licensing December 2011 US\$m	Other Human Health December 2011 US\$m	Intersegment Elimination December 2011 US\$m	Consolidated Group December 2011 US\$m
Sales to external customers	1,883.2	-	440.8	-	2,324.0
Inter-segment sales	66.9	-	-	(66.9)	-
Other revenue / Other income (excl interest income)	2.6	82.4	4.9	-	89.9
<b>Total segment revenue</b>	<b>1,952.7</b>	<b>82.4</b>	<b>445.7</b>	<b>(66.9)</b>	<b>2,413.9</b>
Interest income					14.9
Unallocated revenue / income					0.6
<b>Consolidated revenue</b>					<b>2,429.4</b>
<b>Segment EBIT</b>	<b>583.3</b>	<b>72.9</b>	<b>(5.1)</b>	<b>-</b>	<b>651.1</b>
Unallocated revenue / income less unallocated costs					(17.2)
<b>Consolidated EBIT</b>					<b>633.9</b>
Interest income					14.9
Finance costs					(14.9)
<b>Consolidated profit before tax</b>					<b>633.9</b>
Income tax expense					(129.6)
<b>Consolidated net profit after tax</b>					<b>504.3</b>
Amortisation and impairment loss	14.8	-	-	-	14.8
Depreciation	48.9	-	20.1	-	69.0
<b>Segment EBITDA</b>	<b>647.0</b>	<b>72.9</b>	<b>15.0</b>	<b>-</b>	<b>734.9</b>
Unallocated revenue / income less unallocated costs					(17.3)
Unallocated depreciation and amortisation					2.5
<b>Consolidated EBITDA</b>					<b>720.1</b>
<b>Segment assets</b>	<b>4,180.0</b>	<b>20.2</b>	<b>1,015.9</b>	<b>(153.0)</b>	<b>5,063.1</b>
Other unallocated assets					2,200.0
Elimination of amounts between operating segments and unallocated					(1,339.3)
<b>Total assets</b>					<b>5,923.8</b>
<b>Segment liabilities</b>	<b>1,814.2</b>	<b>3.6</b>	<b>776.9</b>	<b>(153.0)</b>	<b>2,441.7</b>
Other unallocated liabilities					1,156.8
Elimination of amounts between operating segments and unallocated					(1,339.3)
<b>Total liabilities</b>					<b>2,259.2</b>

CSL Interim Financial Statements for the six months ended 31 December 2011  
presented in USD for the information of shareholders

**CSL Limited**  
**Notes to the Financial Statements in USD**  
**For the half-year ended 31 December 2011**

**1 Segment information (continued)**

Geographic areas	Australia US\$m	United States US\$m	Switzerland US\$m	Germany US\$m	Rest of world US\$m	Total US\$m
<b>December 2011</b>						
External sales revenue	286.3	899.0	76.6	356.9	705.2	<b>2,324.0</b>

**2 Revenue, Income and Expenses from continuing operations**

	Consolidated Entity December 2011 US\$m
<b>(a) Other Revenue</b>	
Interest income	14.9
Rent	0.6
Royalties	64.6
Sundry	25.3
	<b>105.4</b>
<b>(b) Finance Costs</b>	
Interest paid / payable	14.9
<b>(c) Other Expenses</b>	
General and administration expenses:	
Expense of share based payments	11.7
Amortisation of intellectual property and software	14.8
Other relevant expenses	
Depreciation and amortisation of property, plant and equipment	71.5
Net foreign exchange losses	4.7

**3 Income Tax**

The reconciliation between income tax expense and the consolidated entity's applicable tax rate is as follows:

Profit from continuing activities before income tax expense	<b>633.9</b>
Income tax calculated at 30%	<b>190.2</b>
Tax effect of non-assessable / non-deductible items	
Research and development	(6.4)
Other (non-assessable revenue)/non-deductible expenses	2.1
(Utilisation of tax losses)/Unrecognised deferred tax assets	-
Effects of different rates of tax on overseas income	(53.7)
Under (over) provision in previous year	(2.6)
Income tax expense	<b>129.6</b>

**CSL Limited**  
**Notes to the Financial Statements in USD**  
**For the half-year ended 31 December 2011**

**4 Earnings Per Share**

**Consolidated Entity**  
**December**  
**2011**  
**US\$m**

The following reflects the income and share information used in the calculation of basic and diluted earnings per share:

Earnings used in calculating basic earnings per share	<b>504.3</b>
<hr/>	
	<b>Number of shares</b>
	<b>December</b>
	<b>2011</b>
Weighted average number of ordinary shares used in the calculation of basic earnings per share:	<b>523,991,134</b>
<b>Effect of dilutive securities:</b>	
Share options	<b>107,358</b>
Performance rights	<b>898,462</b>
Global employee share plan	<b>7,377</b>
<hr/>	
Adjusted weighted average number of ordinary shares used in calculating diluted earnings per share	<b>525,004,331</b>

\*Refer note 10 for a reconciliation of the movement in issued shares.

**5 Cash and cash equivalents**

**Consolidated Entity**  
**December**      **June**  
**2011**            **2011**  
**US\$m**            **US\$m**

Cash at bank and on hand	<b>268.7</b>	<b>316.9</b>
Cash deposits	<b>1,048.5</b>	<b>198.3</b>
<hr/>		
Total cash and cash equivalents	<b>1,317.2</b>	<b>515.2</b>

**6 Property, Plant and Equipment**

During the half-year ended 31 December 2011, the Group acquired assets with a cost of US\$148.4m.

**CSL Limited**  
**Notes to the Financial Statements in USD**  
**For the half-year ended 31 December 2011**

**7 Borrowings and repayments**

For the half year ended 31 December 2011, the Group has repaid US\$14.5m of interest bearing debt, made US\$1.9m of finance lease repayments, and refinanced US\$225.8m of bank debt, a total of US\$242.2m.

During the half the year the Group established several new debt facilities to refinance maturing bank debt and to fund Corporate initiatives including the A\$900m share buyback announced on 19 October 2011. The new debt facilities consist of the following:

- (i) US\$750m Private Placement with maturities in November 2018 (US\$200m), November 2021 (US\$250m), November 2023 (US\$200m) and November 2026 (US\$100m). The weighted average interest rate on the Private Placement is 3.81%;
- (ii) US\$430m and EUR155m Syndicated bank facility that matures in November 2016. As at balance date US\$100m and EUR100m has been drawn under this facility;
- (iii) US\$105m Syndicated bank facility that matures in November 2016. As at balance date US\$50m has been drawn under this facility; and
- (iv) A fully drawn JPY6b bilateral bank facility that matures in November 2016.
- (v) The total proceeds received from the above facilities during the six months ending 31 December 2011 were US\$1,112.4m.

As at balance date the Group had US\$456m in undrawn liquidity available under its bank debt facilities.

**8 Contributed Equity**

Movements in the contributed equity

	Number of Shares	US\$m
<i>Ordinary shares</i>		
<b>Balance as at 1 July 2011</b>	<b>524,840,532</b>	<b>(228.0)</b>
Shares issued to CSL employees through participation in:		
- Performance Option Plan	63,160	1.1
- Performance Rights Plan	121,296	-
- Global Employee Share Plan	102,776	2.7
Shares acquired under the Share Buy Back	(5,761,762)	(181.8)
<b>Balance as at 31 December 2011</b>	<b>519,366,002</b>	<b>(406.0)</b>

**CSL Limited**  
**Notes to the Financial Statements in USD**  
**For the half-year ended 31 December 2011**

**9 Reserves**

	<b>Consolidated Entity</b>
	<b>December</b>
	<b>2011</b>
	<b>US\$m</b>
<i>Composition</i>	
Share based payments reserve (i)	<b>88.6</b>
Foreign currency translation reserve (ii)	<b>582.1</b>
Available-for-sale investments reserve (iii)	<b>(2.2)</b>
	<b>668.5</b>

**Nature and purpose of reserves**

(i) *Share based payments reserve*

The share based payments reserve is used to recognise the fair value of options and performance rights issued but not exercised.

(ii) *Foreign currency translation reserve*

The results of foreign subsidiaries are translated into US dollars at average exchange rates. Assets and liabilities of foreign subsidiaries are translated to US dollars at exchange rates prevailing at balance date and resulting exchange differences are recognised in the foreign currency translation reserve in equity. On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are taken to the foreign currency translation reserve in equity.

(iii) *Available-for-sale investments reserve*

Changes in the fair value and exchange differences arising on translation of investments classified as available-for-sale financial assets are recognised in other comprehensive income and accumulated in a separate reserve within equity. Amounts are reclassified to profit and loss when the associated assets are sold or impaired.

# CSL Limited

ABN: 99 051 588 348

## **Abbreviated Financial Statements presented in USD for the information of Shareholders**

for the year ended 30 June 2012

These abbreviated financial statements have been prepared using the same accounting policies as applied to the CSL Limited financial statements for the year ended 30 June 2012 issued on 22 August 2012 and available on the Company's website [www.csl.com.au](http://www.csl.com.au),

with the exception of the following:

The financial statements were presented in AUDm while this report adopts a Presentation Currency of USD and is presented in US\$m.

**CSL Limited**  
**Consolidated Statement of Comprehensive Income in USD**  
for the year ended 30 June 2012

		Consolidated Group
	Notes	2012 US\$m
<b>Continuing operations</b>		
Sales revenue	3	4,616.4
Cost of sales		(2,389.9)
<b>Gross profit</b>		<b>2,226.5</b>
Other revenues	3	197.2
Research and development expenses		(369.7)
Selling and marketing expenses		(505.8)
General and administration expenses		(237.7)
Finance costs	3	(40.5)
<b>Profit before income tax expense</b>		<b>1,270.0</b>
Income tax expense	4	(246.1)
<b>Profit attributable to members of the parent company</b>	<b>22</b>	<b>1,023.9</b>
<b>Other comprehensive income</b>		
Exchange differences on translation of foreign operations, net of hedges on foreign investments	21	(364.5)
Actuarial gains/(losses) on defined benefit plans, net of tax	22	(49.2)
Mark to Market adjustment on available-for-sale financial assets	21	1.2
Total of other comprehensive income/(expenses)		(412.5)
<b>Total comprehensive income for the period</b>	<b>24</b>	<b>611.4</b>
<b>Earnings per share</b>		
	5	Cents
Basic earnings per share		197.20
Diluted earnings per share		196.79

*The above consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.*

**CSL Limited**  
**Consolidated Balance Sheet in USD**  
As at 30 June 2012

		Consolidated Group	
		2012	2011
	Notes	US\$m	US\$m
<b>CURRENT ASSETS</b>			
Cash and cash equivalents	6	1,171.4	515.2
Trade and other receivables	7	783.8	869.0
Inventories	8	1,482.7	1,564.8
Current tax assets	16	5.4	0
Other financial assets	9	1.8	19.3
<b>Total Current Assets</b>		<b>3,445.1</b>	<b>2,968.3</b>
<b>NON-CURRENT ASSETS</b>			
Trade and other receivables	7	10.4	4.9
Other financial assets	9	1.1	2.4
Property, plant and equipment	10	1,380.9	1,297.5
Deferred tax assets	11	198.5	187.2
Intangible assets	12	865.3	983.4
Retirement benefit assets	13	0.0	2.8
<b>Total Non-Current Assets</b>		<b>2,456.2</b>	<b>2,478.2</b>
<b>TOTAL ASSETS</b>		<b>5,901.3</b>	<b>5,446.5</b>
<b>CURRENT LIABILITIES</b>			
Trade and other payables	14	536.3	530.4
Interest-bearing liabilities and borrowings	15	169.6	243.1
Current tax liabilities	16	141.7	141.5
Provisions	17	100.3	95.2
Deferred government grants	18	1.0	1.1
Derivative financial instruments	19	1.4	5.4
<b>Total Current Liabilities</b>		<b>950.3</b>	<b>1,016.7</b>
<b>NON-CURRENT LIABILITIES</b>			
Trade and other payables	14	15.4	4.3
Interest-bearing liabilities and borrowings	15	1,120.0	204.3
Deferred tax liabilities	11	111.1	131.3
Provisions	17	28.0	30.6
Deferred government grants	18	30.2	20.3
Retirement benefit liabilities	13	169.6	122.4
<b>Total Non-Current Liabilities</b>		<b>1,474.3</b>	<b>513.2</b>
<b>TOTAL LIABILITIES</b>		<b>2,424.6</b>	<b>1,529.9</b>
<b>NET ASSETS</b>		<b>3,476.7</b>	<b>3,916.6</b>
<b>EQUITY</b>			
Contributed equity	20	(869.1)	(228.0)
Reserves	21	632.9	982.1
Retained earnings	22	3,712.9	3,162.5
<b>TOTAL EQUITY</b>	<b>24</b>	<b>3,476.7</b>	<b>3,916.6</b>

*The above consolidated balance sheet should be read in conjunction with the accompanying notes.*



## CSL Limited

# Consolidated Statement of Changes in Equity in USD

for the year ended 30 June 2012

Consolidated Group	Notes	Contributed Equity US\$m	Foreign currency translation reserve US\$m	Share based payment reserve US\$m	Available- for-sale investment reserve US\$m	Retained earnings US\$m	Total US\$m
<b>At 1 July 2011</b>		<b>(228.0)</b>	<b>901.1</b>	<b>82.2</b>	<b>(1.2)</b>	<b>3,162.5</b>	<b>3,916.6</b>
Profit for the period		-	-	-	-	1,023.9	1,023.9
Other comprehensive income		-	(364.5)	-	1.2	(49.2)	(412.5)
<b>Total comprehensive income for the full year</b>		<b>-</b>	<b>(364.5)</b>	<b>-</b>	<b>1.2</b>	<b>974.7</b>	<b>611.4</b>
<b>Transactions with owners in their capacity as owners</b>							
Share based payments	21	-	-	14.1	-	-	14.1
Dividends	23	-	-	-	-	(424.3)	(424.3)
Share buy back	20	(650.1)	-	-	-	-	(650.1)
Share issues							
- Employee share scheme	20	9.0	-	-	-	-	9.0
<b>Balance as at 30 June 2012</b>		<b>(869.1)</b>	<b>536.6</b>	<b>96.3</b>	<b>-</b>	<b>3,712.9</b>	<b>3,476.7</b>

*The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.*

**CSL Limited**  
**Consolidated Statement of Cash Flows in USD**  
for the year ended 30 June 2012

	Consolidated Group	
	Notes	2012 US\$m
<b>Cash flows from Operating Activities</b>		
Receipts from customers		4,839.5
Payments to suppliers and employees		(3,383.1)
Cash generated from operations		1,456.4
Income taxes paid		(252.3)
Interest received		37.2
Finance costs paid		(35.5)
<b>Net cash inflow from operating activities</b>	<b>25</b>	<b>1,205.8</b>
<b>Cash flows from Investing Activities</b>		
Proceeds from sale of property, plant and equipment		0.1
Payments for property, plant and equipment		(309.2)
Payments for intangible assets		(14.2)
Receipts from other financial assets		1.1
<b>Net cash outflow from investing activities</b>		<b>(322.2)</b>
<b>Cash flows from Financing Activities</b>		
Proceeds from issue of shares		10.3
Dividends paid	23	(424.3)
Proceeds from borrowings		1,112.4
Repayment of borrowings		(243.6)
Payment for shares bought back		(650.1)
Payment for settlement of finance hedges		0.6
<b>Net cash outflow from financing activities</b>		<b>(194.7)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>688.9</b>
Cash and cash equivalents at the beginning of the financial year		514.6
Exchange rate variations on foreign cash and cash equivalent balances		(35.4)
<b>Cash at the end of the financial year</b>	<b>25</b>	<b>1,168.1</b>

For non-cash financing activities refer to note 25.

*The above consolidated cash flow statement should be read in conjunction with the accompanying notes.*

# CSL Limited and its controlled entities

## Notes to the Financial Statements in USD

for the year ended 30 June 2012

### 1. Corporate information

CSL Limited is a for-profit company incorporated and domiciled in Australia and limited by shares publicly traded on the Australian Securities Exchange.

#### Summary of significant accounting policies

The accounting policies adopted in the preparation of the USD financial report are identical to those detailed in Note 1 of CSL Limited's Financial Report for the year ended 30 June 2012 published in the CSL Limited Annual Report, with the exception of the presentation currency noted below.

#### (a) Foreign currency translation

##### *i. Functional and presentation currency*

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates ('the functional currency').

The financial statements of CSL Limited (the parent entity of the Group) are measured in Australian Dollars which is that entity's functional currency.

The consolidated financial statements are presented in US dollars, which is the Group's presentation currency.

##### *ii. Translation and balances*

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in functional currencies are recognised in the statement of comprehensive income, except when deferred in equity as qualifying cash flow hedges and qualifying net investment hedges or are attributable to part of the net investment in a foreign operation.

##### *iii. Group companies*

The results of foreign subsidiaries are translated into US dollars at average exchange rates. Assets and liabilities of foreign subsidiaries are translated to US dollars at exchange rates prevailing at balance date. All resulting exchange differences are recognised in other comprehensive income and in the foreign currency translation reserve in equity.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognised in other comprehensive income and in the foreign currency translation reserve in equity. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, a proportionate share of such exchange differences are recognised in the statement of comprehensive income, as part of the gain on sale or loss on sale where applicable.

# CSL Limited and its controlled entities

## Notes to the Financial Statements in USD

for the year ended 30 June 2012

### 2 Segment Information

#### Description of Segments

Reportable segments are:

- CSL Behring – manufactures markets and develops plasma products.
- Intellectual Property Licensing – revenue and associated expenses from the licensing of Intellectual Property generated by the Group to unrelated third parties.
- Other Human Health – comprises CSL Bioplasma and CSL Biotherapies. These businesses manufacture and distribute biotherapeutic products and are disclosed in aggregate as they exhibit similar economic characteristics.

#### Geographical areas of operation

The Group operates predominantly in four specific geographic areas, namely Australia, the United States of America, Switzerland, and Germany. The rest of the Group's operations are spread across many countries and are collectively disclosed as 'Rest of World' in note 2.

#### Segment Accounting Policies

Inter-segment sales are carried out on an arm's length basis and reflect current market prices. Segment accounting policies are the same as the Group's policies described in note 1. During the financial year, there were no changes in segment accounting policies.

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

**2 Segment Information (continued)**

	CSL Behring 2012 US\$m	Intellectual Property Licensing 2012 US\$m	Other Human Health 2012 US\$m	Intersegment Elimination 2012 US\$m	Consolidated Group 2012 US\$m
Sales to external customers	3,763.1	-	853.3	-	4,616.4
Inter-segment sales	145.4	-	-	(145.4)	-
Other revenue (excl interest income)	4.7	142.3	8.3	-	155.3
<b>Total segment revenue</b>	<b>3,913.2</b>	<b>142.3</b>	<b>861.6</b>	<b>(145.4)</b>	<b>4,771.7</b>
Interest income					42.8
Unallocated revenue / income					(0.9)
<b>Consolidated revenue</b>					<b>4,813.6</b>
<b>Segment EBIT</b>	<b>1,230.9</b>	<b>125.7</b>	<b>(38.2)</b>	<b>-</b>	<b>1,318.4</b>
Unallocated revenue / income less unallocated costs					(50.7)
<b>Consolidated EBIT</b>					<b>1,267.7</b>
Interest income					42.8
Finance costs					(40.5)
<b>Consolidated profit before tax</b>					<b>1,270.0</b>
Income tax expense					(246.1)
<b>Consolidated net profit after tax</b>					<b>1,023.9</b>
Amortisation	29.7	-	-	-	29.7
Depreciation	98.0	-	44.9	-	142.9
<b>Segment EBITDA</b>	<b>1,358.6</b>	<b>125.7</b>	<b>6.7</b>	<b>-</b>	<b>1,491.0</b>
Unallocated revenue / income less unallocated costs					(50.7)
Unallocated depreciation and amortisation					5.4
<b>Consolidated EBITDA</b>					<b>1,445.7</b>
<b>Segment assets</b>	<b>4,270.9</b>	<b>21.2</b>	<b>1,087.3</b>	<b>(168.2)</b>	<b>5,211.2</b>
Other unallocated assets					1,598.1
Elimination of amounts between operating segments and unallocated					(908.0)
<b>Total assets</b>					<b>5,901.3</b>
<b>Segment liabilities</b>	<b>1,856.6</b>	<b>4.0</b>	<b>496.8</b>	<b>(168.2)</b>	<b>2,189.2</b>
Other unallocated liabilities					1,143.4
Elimination of amounts between operating segments and unallocated					(908.0)
<b>Total liabilities</b>					<b>2,424.6</b>
<b>Other information - capital expenditure</b>					
Payments for property, plant and equipment	188.3	-	120.9	-	309.2
Payments for software intangibles	14.2	-	-	-	14.2
<b>Total capital expenditure</b>	<b>202.5</b>	<b>-</b>	<b>120.9</b>	<b>-</b>	<b>323.4</b>

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

**2 Segment Information (continued)**

<b>Geographic areas</b>	<b>Australia</b>	<b>United States</b>	<b>Switzerland</b>	<b>Germany</b>	<b>Rest of world</b>	<b>Total</b>
<b>June 2012</b>	<b>US\$m</b>	<b>US\$m</b>	<b>US\$m</b>	<b>US\$m</b>	<b>US\$m</b>	<b>US\$m</b>
External sales revenue	604.1	1,774.6	146.5	678.8	1,412.4	4,616.4
Property, plant, equipment and intangible assets	553.0	472.0	969.0	238.8	13.4	2,246.2

		<b>Consolidated Group</b>
		<b>2012</b>
		<b>US\$m</b>

**3 Revenue and expenses from continuing operations**

<b>Revenue</b>		
Sales revenue		4,616.4
<b>Other revenue</b>		
Royalties and licence revenue		142.3
Finance revenue		42.8
Rent		1.3
Other revenue		10.8
Total other revenues		197.2
Total revenue from continuing operations		4,813.6
<b>Finance revenue comprises:</b>		
Interest income:		
Other persons and/or corporations		42.8
Total finance revenue		42.8
<b>Finance costs</b>		
Interest expense:		
Other persons and/or corporations		40.5
Total finance costs		40.5

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

	<b>Consolidated Group</b>	
	<b>Notes</b>	<b>2012 US\$m</b>
<b>3 Revenue and expenses (continued)</b>		
<b>Depreciation and amortisation</b>		
Depreciation and amortisation of fixed assets		
Building depreciation	10	13.9
Plant and equipment depreciation	10	125.4
Leased property, plant and equipment amortisation	10	3.0
Leasehold improvements amortisation	10	6.1
<b>Total depreciation and amortisation of fixed assets</b>		<b>148.4</b>
Amortisation of intangibles		
Intellectual property	12	18.8
Software	12	10.8
<b>Total amortisation of intangibles</b>		<b>29.6</b>
Impairment loss		
Intellectual property	12	-
<b>Total depreciation, amortisation and impairment expense</b>		<b>178.0</b>
<b>Other expenses</b>		
Write-down of inventory to net realisable value		78.5
Doubtful debts		27.1
Net loss on disposal of property, plant and equipment		2.5
Net foreign exchange loss		7.7
<b>Lease payments and related expenses</b>		
Rental expenses relating to operating leases		34.7
<b>Employee benefits expense</b>		
Salaries and wages		985.1
Defined benefit plan expense		20.6
Defined contribution plan expense		19.8
Share based payments expense (LTI)	21	12.1
Share based payments expense (EDIP)		11.7
<b>Total employee benefits expense</b>		<b>1,049.3</b>

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		Consolidated Group
		2012
		US\$m
	Notes	
<b>4 Income tax expense</b>		
<b>Income tax expense recognised in the statement of comprehensive income</b>		
<b>Current tax expense</b>		
Current year		266.1
<b>Deferred tax expense</b>		
Origination and reversal of temporary differences	11	(19.4)
Tax losses recognised		-
Total deferred tax expense		(19.4)
Over provided in prior years		(0.6)
Income tax expense		246.1
<b>Reconciliation between tax expense and pre-tax net profit</b>		
The reconciliation between tax expense and the product of accounting profit before income tax multiplied by the Group's applicable income tax rate is as follows:		
Accounting profit before income tax		1270.0
Income tax calculated at 30%		381.0
Research and development		(10.7)
Other non-deductible items		4.1
Utilisation of tax losses/unrecognised deferred tax		-
Effects of different rates of tax on overseas income		(127.7)
Over provision in prior year		(0.6)
Income tax expense		246.1
<b>Income tax recognised directly in equity</b>		
<b>Deferred tax benefit</b>		
Share based payments		1.0
Income tax benefit recognised in equity	11	1.0



**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		<b>Consolidated Group</b>
		<b>2012</b>
		<b>US\$m</b>
<b>5 Earnings Per Share</b>		
Earnings used in calculating basic and dilutive earnings per share comprises:		
Profit attributable to ordinary shareholders		<b>1,023.9</b>
		<b>Number of shares</b>
		<b>2012</b>
Weighted average number of ordinary shares used in the calculation of basic earnings per share:		<b>519,233,274</b>
Effect of dilutive securities:		
Employee options		<b>95,871</b>
Employee performance rights		<b>965,977</b>
Global employee share plan		<b>9,380</b>
Adjusted weighted average number of ordinary shares used in the calculation of diluted earnings per share:		<b>520,304,502</b>

***Options and performance rights***

Options and performance rights granted to employees are considered to be potential ordinary shares that have been included in the determination of diluted earnings per share to the extent to which they are dilutive. The options and rights have not been included in the determination of basic earnings per share.

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

	<b>Consolidated Group</b>	
	<b>2012</b>	<b>2011</b>
	<b>US\$m</b>	<b>US\$m</b>
<b>6 Cash and cash equivalents</b>		
Cash at bank and on hand	342.3	316.9
Cash deposits	829.1	198.3
<b>Total cash and cash equivalents</b>	<b>1,171.4</b>	<b>515.2</b>
Note 25(a) contains a reconciliation of the above figures to cash at the end of the financial year as shown in the statement of cash flows.		
<b>7 Trade and other receivables</b>		
<b>Current</b>		
Trade receivables	723.6	789.2
Less: Provision for impairment loss <i>(i)</i>	(46.2)	(24.6)
	<b>677.4</b>	<b>764.6</b>
Sundry receivables	77.7	72.1
Prepayments	28.7	32.3
<b>Carrying amount of current trade and other receivables</b>	<b>783.8</b>	<b>869.0</b>
<b>Non-Current</b>		
Related parties		
Loans to other employees	0.1	1.2
Long term deposits	3.6	-
Other receivables	6.7	3.7
<b>Carrying amount of non-current trade and other receivables</b>	<b>10.4</b>	<b>4.9</b>

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		<b>Consolidated Group</b>	
		<b>2012</b>	<b>2011</b>
		<b>US\$m</b>	<b>US\$m</b>
<b>8</b>	<b>Inventories</b>		
	Raw materials and stores at the lower of cost and net realisable value	<b>320.9</b>	<b>306.6</b>
	Work in progress at the lower of cost and net realisable value	<b>421.2</b>	<b>497.0</b>
	Finished goods at the lower of cost and net realisable value	<b>740.6</b>	<b>761.2</b>
	Total inventories at the lower of cost and net realisable value	<b>1,482.7</b>	<b>1,564.8</b>
<b>9</b>	<b>Other financial assets</b>		
	<b>Current</b>		
	At fair value through the profit or loss:		
	Managed financial assets (held for trading)	<b>1.8</b>	<b>19.3</b>
	Available-for-sale financial assets	<b>-</b>	<b>-</b>
	Total current other financial assets as at 30 June	<b>1.8</b>	<b>19.3</b>
	<b>Non-current</b>		
	At fair value through the profit or loss:		
	Managed financial assets	<b>1.1</b>	<b>2.4</b>
	Total non-current other financial assets as at 30 June	<b>1.1</b>	<b>2.4</b>

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		<b>Consolidated Group</b>	
		<b>2012</b>	<b>2011</b>
		<b>US\$m</b>	<b>US\$m</b>
<b>10</b>	<b>Property, Plant and Equipment</b>		
	<b>Land at cost</b>		
	Opening balance 1 July	27.2	
	Currency translation differences	(1.6)	
	Closing balance 30 June	25.6	27.2
	<b>Buildings at cost</b>		
	Opening balance 1 July	305.1	
	Transferred from capital work in progress	17.5	
	Disposals	(0.6)	
	Currency translation differences	(25.8)	
	Closing balance 30 June	296.2	305.1
	Accumulated depreciation and impairment losses		
	Opening balance 1 July	82.5	
	Depreciation for the year	13.9	
	Disposals	(0.4)	
	Currency translation differences	(8.5)	
	Closing balance 30 June	87.5	82.5
	Net book value of buildings	208.7	222.6
	Net book value of land and buildings	234.3	249.8
	<b>Leasehold improvements at cost</b>		
	Opening balance 1 July	68.5	
	Transferred from capital work in progress	16.6	
	Other additions	0.5	
	Disposals	(0.9)	
	Currency translation differences	(0.3)	
	Closing balance 30 June	84.4	68.5
	Accumulated amortisation and impairment		
	Opening balance 1 July	21.5	
	Amortisation for the year	6.1	
	Disposals	(0.8)	
	Currency translation differences	0.2	
	Closing balance 30 June	27.0	21.5
	Net book value of leasehold improvements	57.4	47.0

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		Consolidated Group	
		2012	2011
		US\$m	US\$m
<b>10</b>	<b>Property, Plant and Equipment (continued)</b>		
	<b>Plant and equipment at cost</b>		
	Opening balance 1 July	1,628.1	
	Transferred from capital work in progress	137.7	
	Other additions	16.9	
	Disposals	(18.9)	
	Currency translation differences	(142.2)	
	Closing balance 30 June	1,621.6	1,628.1
	Accumulated depreciation and impairment		
	Opening balance 1 July	819.0	
	Depreciation for the year	125.4	
	Disposals	(18.0)	
	Currency translation differences	(73.8)	
	Closing balance 30 June	852.6	819.0
	Net book value of plant and equipment	769.0	809.1
	<b>Leased property, plant and equipment at cost</b>		
	Opening balance 1 July	35.3	
	Other additions	1.1	
	Disposals	(1.3)	
	Currency translation differences	(4.2)	
	Closing balance 30 June	30.9	35.3
	Accumulated amortisation and impairment		
	Opening balance	15.4	
	Amortisation for the year	3.0	
	Disposals	(0.9)	
	Currency translation differences	(2.5)	
	Closing balance 30 June	15.0	15.4
	Net book value of leased property, plant and equipment	15.9	19.9
	<b>Capital work in progress</b>		
	Opening balance 1 July	171.8	
	Other additions	324.6	
	Disposals	(1.0)	
	Transferred to buildings at cost	(17.5)	
	Transferred to plant and equipment at cost	(137.7)	
	Transferred to leasehold improvements at cost	(16.6)	
	Currency translation differences	(19.3)	
	Closing balance 30 June	304.3	171.8
	<b>Total net book value of property, plant and equipment</b>	<b>1,380.9</b>	<b>1,297.5</b>

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

	Consolidated Group	
	2012	2011
	US\$m	US\$m
<b>11 Deferred tax assets and liabilities</b>		
Deferred tax asset	198.5	187.2
Deferred tax liability	(111.1)	(131.3)
<b>Net deferred tax asset/(liability)</b>	<b>87.4</b>	<b>55.9</b>
<b>Deferred tax balances reflect temporary differences attributable to:</b>		
Amounts recognised in the statement of comprehensive income		
Trade and other receivables	(8.8)	
Inventories	91.8	
Property, plant and equipment	(71.5)	
Intangible assets	(43.1)	
Other assets	(0.6)	
Trade and other payables	10.5	
Interest bearing liabilities	3.9	
Other liabilities and provisions	50.9	
Retirement assets/(liabilities)	30.6	
Tax bases not in net assets – share based payments	10.4	
Recognised carry-forward tax losses	8.6	
	<b>82.7</b>	
Amounts recognised in equity		
Capital raising costs	1.8	
Share based payments	2.9	
	<b>4.7</b>	
<b>Net deferred tax asset/(liability)</b>	<b>87.4</b>	
<b>Movement in temporary differences during the year</b>		
Opening balance	55.9	
Credited/(charged) to profit before tax	19.4	
Credited/(charged) to other comprehensive income	15.9	
Credited/(charged) to equity	1.0	
Currency translation difference	(4.8)	
Closing balance	<b>87.4</b>	
<b>Unrecognised deferred tax assets</b>		
Deferred tax assets have not been recognised in respect of the following items:		
Tax losses:		
Expiry date in less than 1 year	0.1	
Expiry date greater than 1 year but less than 5 years	-	
Expiry date greater than 5 years	-	
No expiry date	0.7	
	<b>0.8</b>	

Deferred tax assets have not been recognised in respect of these items because it is not probable that future taxable profit will be available for utilisation in the entities that have recorded these losses.

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		<b>Consolidated Group</b>	
		<b>2012</b>	<b>2011</b>
		<b>US\$m</b>	<b>US\$m</b>
<b>12</b>	<b>Intangible Assets</b>		
	<b>Carrying amounts</b>		
	<b>Goodwill</b>		
	Opening balance at 1 July	766.0	
	Currency translation differences	(83.8)	
	Closing balance at 30 June	682.2	766.0
	<b>Intellectual property</b>		
	Opening balance at 1 July	381.4	
	Additions	0.6	
	Disposals	(1.6)	
	Currency translation differences	(35.2)	
	Closing balance at 30 June	345.2	381.4
	Accumulated amortisation and impairment		
	Opening balance at 1 July	213.7	
	Amortisation for the year	18.8	
	Currency translation differences	(18.9)	
	Closing balance at 30 June	213.6	213.7
	Net intellectual property	131.6	167.7
	<b>Software</b>		
	Opening balance at 1 July	58.5	
	Additions	0.6	
	Transfers from intangible capital work in progress	15.0	
	Currency translation differences	(2.1)	
	Closing balance at 30 June	72.0	58.5
	Accumulated amortisation and impairment		
	Opening balance at 1 July	20.2	
	Amortisation for the year	10.8	
	Currency translation differences	(1.1)	
	Closing balance at 30 June	29.9	20.2
	Net Software	42.1	38.3
	<b>Intangible capital work in progress</b>		
	Opening balance at 1 July	11.4	
	Additions	13.3	
	Transfers to software intangibles	(15.0)	
	Currency translation differences	(0.3)	
	Closing balance at 30 June	9.4	11.4
	<b>Total net intangible assets as at 30 June</b>	<b>865.3</b>	<b>983.4</b>

The amortisation charge is recognised in general and administration expenses in the statement of comprehensive income.

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

**Consolidated Group**

**2012**  
**US\$m**

**12 Intangible Assets (continued)**

**Impairment tests for cash generating units containing goodwill**

For the purpose of impairment testing, goodwill is allocated to the business unit which represents the lowest level within the Group at which the goodwill is monitored for internal management purposes. The aggregate carrying amounts of goodwill allocated to each unit are as follows:

CSL Behring	<b>669.9</b>
CSL Biotherapies	<b>12.3</b>
Closing balance of goodwill as at 30 June	<b>682.2</b>

The impairment tests for these cash generating units are based on value in use calculations. These calculations use cash flow projections based on actual operating results and the three-year strategic business plan, after which a terminal value is calculated based on a business valuation multiple. The valuation multiple has been calculated based on independent external analyst views, long term government bond rates and the company's pre-tax cost of debt. Projected cash flows have been discounted by using the implied pre-tax discount rate of 8.4% associated with the business valuation multiple discussed above. Each unit's recoverable amount exceeds the carrying value of its net assets, inclusive of goodwill. It is not considered a reasonable possibility for a change in assumptions to occur that would lead to a unit's recoverable amount falling below the carrying value of each unit's respective net assets.



**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		<b>Consolidated Group</b>	
		<b>2012</b>	<b>2011</b>
		<b>US\$m</b>	<b>US\$m</b>
<b>13</b>	<b>Retirement benefit assets and liabilities</b>		
	<b>Retirement benefit assets</b>		
	Non-current defined benefit plans (refer note 26)	-	2.8
	<b>Retirement benefit liabilities</b>		
	Non-current defined benefit plans (refer note 26)	169.6	122.4
<b>14</b>	<b>Trade and other payables</b>		
	<b>Current</b>		
	Trade payables	220.9	263.0
	Accruals and other payables	315.4	267.4
	Carrying amount of current trade and other payables	536.3	530.4
	<b>Non-current</b>		
	Share based payments (EDIP)	15.4	4.3
	Carrying amount of non-current trade and other payables	15.4	4.3
<b>15</b>	<b>Interest-bearing liabilities and borrowings</b>		
	<b>Current</b>		
	Bank overdrafts – Unsecured	3.3	0.6
	Bank loans – Unsecured (a)	-	224.7
	Senior Unsecured Notes - Unsecured (b)	163.4	14.7
	Lease liability – Secured (c)	2.9	3.1
		169.6	243.1
	<b>Non-current</b>		
	Bank loans – Unsecured (a)	351.4	-
	Senior Unsecured Notes - Unsecured (b)	744.8	175.1
	Lease liability - Secured (c)	23.8	29.2
		1,120.0	204.3

- (a) The Group has three revolving committed bank facilities. These facilities mature in November 2016. Interest on the facilities is paid quarterly in arrears at a variable rate. As at the reporting date the Group had US\$454.2m in undrawn funds available under these facilities.
- (b) Represents US\$844.1 million and Euro 55.9 million of Senior Unsecured Notes placed into the US Private Placement market. The Euro notes and US\$94.1 million of the US\$ notes mature in December 2012. The balance of the US\$ notes mature in November 2018 (US\$200m), November 2021 (US\$250m), November 2023 (US\$200m) and November 2026 (US\$100m). The weighted average interest rate on the notes is fixed at 4.04% for the US\$ notes and 4.67% for the Euro notes.
- (c) Finance leases have an average lease term of 12 years. The weighted average discount rate implicit in the leases is 5.75%. The Group's lease liabilities are secured by leased assets of US\$15.9m. In the event of default, leased assets revert to the lessor.

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		<b>Consolidated Group</b>	
		<b>2012</b>	<b>2011</b>
		<b>US\$m</b>	<b>US\$m</b>
<b>16</b>	<b>Tax liabilities</b>		
	Current tax receivable	5.4	-
		<b>5.4</b>	<b>-</b>
	Current tax liability	141.7	141.5
		<b>141.7</b>	<b>141.5</b>
<b>17</b>	<b>Provisions</b>		
	<b>Current</b>		
	Employee benefits	81.7	76.9
	Restructuring	6.6	4.4
	Onerous contracts	10.3	11.9
	Other	1.7	2.0
		<b>100.3</b>	<b>95.2</b>
	<b>Non-current</b>		
	Employee benefits	27.2	29.4
	Other	0.8	1.2
		<b>28.0</b>	<b>30.6</b>

**Restructuring**

A restructuring provision is recognised when the main features of the restructuring are planned. Restructuring plans must set out the businesses, locations and approximate number of employees affected and the expenditures that will be undertaken, together with an implementation timetable. There must be a demonstrable commitment and valid expectation in those affected that the restructuring plan will be implemented prior to a provision being recognised.

**Onerous contracts**

The provision recognised is based on the excess of the estimated cash flows to meet the unavoidable costs, over the estimated cash flows to be received in relation to certain contracts, having regard to the risks of the activities relating to the contracts.

**Discounting**

Where the effect of discounting is determined to be material to the provision, the net estimated cash flows are discounted using a pre-tax discount rate reflecting current market assessments of the time value of money and the risks specific to the liability.

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		<b>Consolidated Group</b>	
		<b>2012</b>	<b>2011</b>
		<b>US\$m</b>	<b>US\$m</b>
<b>17</b>	<b>Provisions (continued)</b>		
	<b>Movements in provisions</b>		
	<i>Restructuring</i>		
	Opening balance	4.4	
	Provided	3.4	
	Payments made	(1.1)	
	Currency differences	(0.1)	
	Closing balance	6.6	4.4
	<i>Onerous contracts</i>		
	Opening balance	11.9	
	Currency differences	(1.6)	
	Closing balance	10.3	11.9
	<i>Other</i>		
	Opening balance	3.2	
	Additional provision	0.3	
	Payments made	(0.6)	
	Currency differences	(0.4)	
	Closing balance	2.5	3.2
<b>18</b>	<b>Deferred government grants</b>		
	Current deferred income	1.0	1.1
	Non-current deferred income	30.2	20.3
	Total deferred government grants	31.2	21.4
<b>19</b>	<b>Derivative financial instruments – current liabilities</b>		
	Forward Currency Contracts	1.4	5.4

The Group has entered into forward currency contracts as an economic hedge against variations in the value of certain trade payable amounts due to currency fluctuations. All movements in the fair value of these forward currency contracts are recognised in the profit and loss when they occur.

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

	<b>Consolidated Group</b>	
	<b>2012</b>	<b>2011</b>
	<b>US\$m</b>	<b>US\$m</b>
<b>20 Contributed equity</b>		
Ordinary shares issued and fully paid	-	-
Share buy-back reserve	<b>(869.1)</b>	<b>(228.0)</b>
<b>Total contributed equity</b>	<b>(869.1)</b>	<b>(228.0)</b>

Ordinary shares have the right to receive dividends as declared and, in the event of winding up the company, to participate in the proceeds from the sale of all surplus assets in proportion to the number of and amounts paid up on shares held. Ordinary shares entitle their holder to one vote, either in person or proxy, at a meeting of the company.

Due to share buy-backs, the balance for ordinary share contributed equity has been reduced to nil, and a reserve created to reflect the excess of shares bought over the original amount of subscribed capital.

	<b>2012</b>	
	<b>Number of shares</b>	<b>US\$m</b>
<b>Movement in contributed equity</b>		
Opening balance at 1 July	<b>524,840,532</b>	<b>(228.0)</b>
Shares issued to employees via:		
- Performance Options (i)	<b>163,814</b>	<b>3.6</b>
- Performance Rights (for nil consideration)	<b>240,178</b>	<b>-</b>
- GESP (ii)	<b>207,576</b>	<b>5.4</b>
Share buy-back, inclusive of cost	<b>(18,522,253)</b>	<b>(650.1)</b>
Closing balance	<b>506,929,847</b>	<b>(869.1)</b>

	<b>Consolidated Group</b>	
	<b>2012</b>	
	<b>US\$m</b>	
(i) Options exercised under Performance Option plans as disclosed in note 27 were as follows		
- 128,670 issued at AU\$17.48		<b>2.3</b>
- 30,849 issued at AU\$35.46		<b>1.1</b>
- 4,295 issued at AU\$37.91		<b>0.2</b>
		<b>3.6</b>
(ii) Shares issued to employees under Global Employee Share Plan (GESP) as disclosed in note 27 were as follows:		
- 102,876 issued at AU\$24.17 on 7 September 2011		<b>2.7</b>
- 104,700 issued at AU\$24.03 on 8 March 2012		<b>2.7</b>
		<b>5.4</b>

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

	Consolidated Group	
	2012 US\$m	2011 US\$m
<b>21 Reserves</b>		
Share based payments reserve	96.3	82.2
Foreign currency translation reserve	536.6	901.1
Available-for-sale investments reserve	-	(1.2)
Carrying value of reserves at 30 June	<b>632.9</b>	<b>982.1</b>
<b>Movements in reserves</b>		
<i>Share based payments reserve (i)</i>		
Opening balance at 1 July	82.2	
Share based payments expense	12.1	
Deferred tax on share based payments	2.0	
Closing balance at 30 June	<b>96.3</b>	<b>82.2</b>
<i>Foreign currency translation reserve (ii)</i>		
Opening balance at 1 July	901.1	
Net exchange gains / (losses) on translation of foreign subsidiaries, net of hedge	(364.5)	
Closing balance at 30 June	<b>536.6</b>	<b>901.1</b>
<i>Available-for-sale investments reserve (iii)</i>		
Opening balance at 1 July	(1.2)	
Mark to market adjustment on available-for-sale financial assets	1.2	
Closing balance at 30 June	-	<b>(1.2)</b>

**Nature and purpose of reserves**

(i) *Share based payments reserve*

The share based payments reserve is used to recognise the fair value of options, performance rights and global employee share plan rights issued to employees.

(ii) *Foreign currency translation reserve*

The foreign currency translation reserve is used to record exchange differences arising from the translation of the financial statements of foreign operations and exchange gains and losses arising on those foreign currency borrowings which are designated as hedging the Company's net investment in foreign operations.

(iii) *Available-for-sale investments reserve*

Changes in the fair value and exchange differences arising on translation of investments classified as available-for-sale financial assets are recognised in other comprehensive income and accumulated in a separate reserve within equity. Amounts are reclassified to profit and loss when the associated assets are sold or impaired.

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		<b>Consolidated Group</b>	
		<b>2012</b>	<b>2011</b>
		<b>US\$m</b>	<b>US\$m</b>
	<b>Note</b>		
<b>22</b>	<b>Retained earnings</b>		
		<b>3,162.5</b>	
		<b>1,023.9</b>	
	<b>23</b>	<b>(424.3)</b>	
		<b>(65.1)</b>	
		<b>15.9</b>	
		<b>3,712.9</b>	<b>3,162.5</b>

**23 Dividends**

**Dividends paid**

Dividends recognised in the current year by the Company are:

Final ordinary dividend of Australian 45 cents per share, franked to 4%, paid on 14 October 2011	<b>231.0</b>
Interim ordinary dividend of Australian 36 cents per share, unfranked, paid on 13 April 2012	<b>193.3</b>
	<b>424.3</b>

**Dividends not recognised at year end**

In addition to the above dividends, since year end the directors have recommended the payment of a final dividend of Australian 47 cents (approximately US\$ 51 cents) per share, unfranked. The final dividend is expected to be paid on 12 October 2012. Based on the number of shares on issue as at reporting date, the aggregate amount of the proposed dividend would be:

**257.2**

The actual aggregate dividend amount paid out of profits will be dependent on the actual number of shares on issue at dividend record date.

**CSL Limited and its controlled entities**  
**Notes to the Financial Statements in USD**  
for the year ended 30 June 2012

		Consolidated Group	
		2012	2011
		US\$m	US\$m
		Notes	
<b>24</b>	<b>Equity</b>		
	Total equity at the beginning of the financial year		3,916.6
	Total comprehensive income for the period		611.4
	Movement in contributed equity	20	(641.1)
	Dividends	23	(424.3)
	Movement in share based payments reserve	21	14.1
	Total equity at the end of the financial year		3,476.7
			3,916.6
<b>25</b>	<b>Statement of Cash Flows</b>		
<b>(a)</b>	<b>Reconciliation of cash and cash equivalents and non-cash financing and investing activities</b>		
	<i>Cash at the end of the year is shown in the cash flow statement as:</i>		
	Cash at bank and on hand	6	342.3
	Cash deposits	6	829.1
	Bank overdrafts	15	(3.3)
			1,168.1
			514.6
<b>(b)</b>	<b>Reconciliation of Profit after tax to Cash Flows from Operations</b>		
	Profit after tax		1,023.9
	Non-cash items in profit after tax		
	Depreciation, amortisation and impairment charges		178.0
	(Gain)/loss on disposal of property, plant and equipment		2.5
	Mark to market adjustment on available-for-sale investments		-
	Share based payments expense		23.8
	Changes in assets and liabilities:		
	(Increase)/decrease in trade and other receivables		2.9
	(Increase)/decrease in inventories		(31.9)
	(Increase)/decrease in retirement benefit assets		2.6
	Increase/decrease in net tax assets and liabilities		(6.2)
	Increase/(decrease) in trade and other payables		1.8
	Increase/(decrease) in provisions		10.6
	Increase/(decrease) in retirement benefit liabilities		(2.2)
	Net cash inflow from operating activities		1,205.8
<b>(c)</b>	<b>Non cash financing activities</b>		
	Acquisition of plant and equipment by means of finance leases		1.1

## **CSL Historical Financial Performance in USD**

### ***Explanatory Notes***

The financial statements have been prepared on the basis that the Group had always reported in USD using the methodology outlined in these explanatory notes.

The Profit & Loss Statement has been converted to USD using the average exchange rate for the relevant period.

The Balance Sheet down to Net Assets (ie Current and Non Current Assets as well as Current and Non Current Liabilities) has been converted to USD using the exchange rate as at the relevant balance date.

Net Assets of A\$3,428.3m as at 30 June 2012 have been converted at an exchange rate of 1.0141 to US\$3,476.7m

The Equity Section of the Balance Sheet has been converted to USD using approximate historical exchange rates.

The application of this approach does generate some significant differences in the Equity section from the Australian Dollar financial statements for the same date:

- Share Capital – the balance is a function of both the Australian Dollar value of transactions and the AUD/USD rate applicable at the relevant transaction date. As a consequence of applying the methodology outlined above the Share Capital balance of (A\$373.3m) at 30 June 2012 is now (US\$869.1m). The majority of this movement is related to the different exchange rates applicable to significant historical movements in Share Capital. CSL has raised equity for acquisitions on four occasions with an average AUD/USD exchange rate of approximately 0.78 and has undertaken share buyback when the average AUD/USD exchange rate was approximately 0.93.
- Retained Earnings – the balance is an accumulation of USD denominated profit generated by the Group, less dividends paid to shareholders. Each dividend has been converted to USD at the payment date and this will not equal the average rate applied to the generation of the underlying profits. Retained Earnings of A\$4,324.5m at 30 June 2012 are now US\$3,712.9m. There is no impact on the Group's ability to pay dividends which are paid by CSL Limited which has a retained earnings balance (recorded in AUD) that is unaffected by the change in presentation currency of the group to USD.
- Reserves
  - Share Based Payments of A\$113.2m at June 2012 is now US\$96.3m
  - FCTR of (A\$636.1m) at June 2012 is now US\$536.6m